▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #282 by analyst upside · 2026-06-27
CUE
Cue Biopharma, Inc.
Healthcare · Market Cap $107M · P/E 0x
ANALYST PRICE TARGET
+352.9%
implied upside to consensus target
Current Price $25.39
Consensus Target $115.0
Bull Target $115.0
Bear Target $115.0
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $4.98
52-Week High $41.42
YTD Return +151.1%
FUNDAMENTALS
Market Cap $107M
P/E Ratio (TTM) N/A
Forward P/E -52.9x
EPS (TTM) $-4.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $33M
Profit Margin -59.6%
52-WEEK RANGE
52-Week Low $4.98
52-Week High $41.42
Current Price $25.39
Bear Target $115.0
Bull Target $115.0
● Now $25.39 ● Target $115.0
TRADING DATA
Avg Volume 748K
YTD Return +151.1%
Analyst Count 1
Consensus Buy
Upside to Target +352.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Cue Biopharma, Inc. (CUE) is currently trading at $25.39 with a Wall Street consensus price target of $115.0, implying potential upside of 352.9% over the next 12 months. 1 analysts currently cover CUE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $115.0, while the most cautious has a target of $115.0.

CUE operates in the Healthcare sector with a market capitalisation of $107M. The stock is up 151.1% year-to-date and is currently trading near the upper end of its 52-week range of $4.98 – $41.42.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

FBIO +298.6%
Fortress Biotech, Inc.
$92M · P/E 0.9x · Buy
PLX +378.3%
Protalix BioTherapeutics, Inc.
$185M · P/E 12.1x · Buy
AGEN +411.6%
Agenus Inc.
$126M · P/E 1.4x · Buy
PALI +414.0%
Palisade Bio, Inc.
$328M · P/E 15.8x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CUE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

LUCID CAPITAL MARKETS ● Initiated
Buy 2025-08-25 40% win rate (5 calls)
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-04-02 Building track record
Stifel — Reiterated
Buy → Buy 2024-08-20 Building track record
JMP Securities — Reiterated
Market Outperform → Market Outperform 2024-07-26 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2024-07-26 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →